- Home
- MSD vs TVRD Comparison
MSD vs TVRD Comparison
Compare MSD & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MSD | TVRD |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.8M | 246.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MSD | TVRD |
|---|---|---|
| Price | $7.35 | $4.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | 70.2K | ★ 123.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 11.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.11 | $3.74 |
| 52 Week High | $7.46 | $43.65 |
Technical Indicators
Market Signals| Indicator | MSD | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 34.35 |
| Support Level | $7.35 | $4.05 |
| Resistance Level | $7.41 | $4.71 |
| Average True Range (ATR) | 0.05 | 0.27 |
| MACD | 0.00 | 0.55 |
| Stochastic Oscillator | 60.71 | 73.20 |
Price Performance
Historical ComparisonAbout MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.